Please use this identifier to cite or link to this item: https://doi.org/10.1517/17425247.2013.777425
Title: Trastuzumab-conjugated vitamin e TPGS liposomes for sustained and targeted delivery of docetaxel
Authors: Raju, A.
Muthu, M.S.
Feng, S.-S. 
Keywords: Cancer nanotechnology
Chemotherapeutic engineering
Drug targeting
Immunoliposomes
Nanomedicine
Solvent injection method
Issue Date: Jun-2013
Source: Raju, A., Muthu, M.S., Feng, S.-S. (2013-06). Trastuzumab-conjugated vitamin e TPGS liposomes for sustained and targeted delivery of docetaxel. Expert Opinion on Drug Delivery 10 (6) : 747-760. ScholarBank@NUS Repository. https://doi.org/10.1517/17425247.2013.777425
Abstract: Objectives: In this study, the authors developed d-α-tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS or simply TPGS) liposomes and further conjugated them to trastuzumab for controlled and targeted delivery of docetaxel (DTX) as a model hydrophobic drug. Methods: DTX-or coumarin-6-loaded liposomes were prepared by solvent injection method and characterized for size and size distribution, surface charge, surface chemistry and drug encapsulation efficiency and drug release profile. SK-BR-3 cells were employed as an in vitro model for HER2-positive breast cancer and assessed for their cellular uptake and cytotoxicity of the two liposomal formulations. In vivo pharmacokinetics (PK) was investigated in Sprague-Dawley rats. Results: The IC50 value was found to be 20.23 ± 1.95, 3.74 ± 0.98, 0.08 ± 0.4 μg/ml for the marketed preparation of DTX, TPGS liposomes and trastuzumab-conjugated TPGS liposomes, respectively after 24 h incubation with SK-BR-3 cells. In vivo PK experiments showed that i.v. administration of trastuzumab-conjugated liposomes achieved 1.9 and 10 times longer half-life, respectively than PEG-coated liposomes and DTX. The area under the curve (AUC) was increased by 3.47-and 1.728-fold, respectively. Conclusion: The trastuzumab-conjugated vitamin E TPGS-coated liposomes showed greater potential for sustained and targeted chemotherapy in the treatment of HER2 overexpressing breast cancer. © 2013 Informa UK, Ltd.
Source Title: Expert Opinion on Drug Delivery
URI: http://scholarbank.nus.edu.sg/handle/10635/64748
ISSN: 17425247
DOI: 10.1517/17425247.2013.777425
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

27
checked on Dec 13, 2017

WEB OF SCIENCETM
Citations

26
checked on Dec 13, 2017

Page view(s)

31
checked on Dec 9, 2017

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.